Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Ceralasertib in Treatment Naïve Extensive Stage Small Cell Lung Cancer
NCT04699838Phase 2Active, not recruiting
- Start
- Apr 2021
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ceralasertib and durvalumab in small cell lung cancer (SCLC). Primary endpoint: Progression Free Survival at 24 months. Started Apr 2021; status: active, not recruiting.
02
Drugs
ceralasertibdurvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04699838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04699838.